Chester County News and Community Website
Ocugen, Inc. (NASDAQ: OCGN), headquartered in Malvern, PA, is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Their breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and their novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, visit www.ocugen.com.
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has reported its first-quarter 2025 financial results and shared updates on its growing pipeline of gene therapy treatments aimed at combating significant unmet …
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) will highlight its pioneering modifier gene therapy platform at two major industry events in May 2025. The company will present its clinical advancements …
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that its Chairman, CEO, and Co-founder, Dr. Shankar Musunuri, will deliver a key presentation at the 2025 Cell & Gene Meeting on …
Ocugen CEO to Present at Prestigious Cell & Gene Meeting on the Mediterranean Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced progress in its Phase 1 clinical trial for OCU200, a novel biologic designed to treat diabetic macular edema (DME) and related eye conditions. …
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results Read More